Advancements in the field of medicine have provided breakthrough treatments to various ailments. Diseases that were considered not treatable are now treated with greater ease. Biotechnology is focused on creating therapies that are genetically targeted, resulting in a focused and effective treatment of ailments. Research on various other diseases is constantly conducted by scientists, which indicates great potential for growth in the healthcare sector. More and more investors are now looking towards health care stocks to grow their money. While this industry has major growth potential, it is also very risky and uncertain.
The prospects of generating a big amount of profit attract investors to biotech stocks. Many other investors prefer staying away from these stocks because there is a great possibility of huge losses due to the high-risk levels with many biotech stocks. Investors must pick biotech stocks only if they are willing to bear the risk. The risk of clinical failure can upset the stock prices while success will positively impact its stocks. If you are planning to invest in this industry, look out for companies that are researching areas like Cancer, AIDS, diabetes, heart diseases, viral infections, neurological and immunological diseases, etc. Success in this area will give the company a faster return on investment, which will, in turn, be beneficial for investors.
A company to look into if you want to invest in biotech is Arbutus Biopharma Corporation. This company was earlier known as Tekmira Pharmaceuticals Corporation and later changed it to its current name in July 2015. This is a biopharmaceutical company that is involved in the discovery, development, and commercialization of a cure for chronic Hepatitis B virus (HBV) infection in Canada and the US. There are several programs that are developing therapies for the same. This company also develops RNAi drugs which allow a novel approach for treatment.
Arbutus Biopharma Corporation is listed on Nasdaq with the ticker ‘ABUS’. The company is headquartered in Burnaby, Canada. Arbutus Biopharma (NASDAQ: ABUS at https://www.webull.com/quote/nasdaq-abus) has a strategic alliance, licensing, and research collaborations with 7 companies: Marqibo, Gritstone Oncology, Acuitas Therapeutics, Alexion Pharmaceuticals, Monsanto Company, Marina Biotech, and Arcturus Therapeutics.
The Nasdaq abus stock has received a consensus rating of ‘buy’ from analysts, out of 5 buy ratings, and 1 sell rating. Analysts are anticipating a price target upside of $5.80, as opposed to the current price of $2.95. NASDAQ: ABUS was trading at $2.85 before Covid-19 attained pandemic status. Currently, the stock is being traded at $2.95 (14.3% increase) on Nasdaq. Its market cap is $191.02 million. Analysts forecast that share price may range from $4 to $10 in the next 12 months. You can do stock trading at the best stock trading platform. Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
